NRF2/ABCB1‐mediated efflux andPARP1‐mediated dampening ofDNAdamage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells-Reference-Cited by-同舟云学术

NRF2/ABCB1‐mediated efflux andPARP1‐mediated dampening ofDNAdamage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells

Published:2019-10-28 Issue:1 Volume:34 Page:41-50
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:Fundam Clin Pharmacol

Author:

Xia Xiangwen¹^ORCID,Wang Qi¹,Ye Tianhe¹,Liu Yiming¹,Liu Dehan¹,Song Songlin¹,Zheng Chuansheng¹

Affiliation:

1. Department of Radiology Union Hospital Tongji Medical College Huazhong University of Science and Technology 1277 Jiefang Avenue Wuhan Hubei 430022 China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/fcp.12505

Reference38 articles.

1. Science to Practice: Killing Dormant Cells—Is Targeting Autophagy the Key to Complete Tumor Response in Transarterial Chemoembolization?

2. Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma

3. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion

4. Experimental Evaluation of Inhibitory Effect of 10-Hydroxycamptothecin on Hypoxia-inducible Factor-1α Expression and Angiogenesis in Liver Tumors after Transcatheter Arterial Embolization

5. Screening and identification of a specific peptide for targeting hypoxic hepatoma cells

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells;Cancers;2024-04-29

2. Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review);International Journal of Oncology;2023-08-28

3. Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy;Current Molecular Pharmacology;2023-06

4. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment;Frontiers in Oncology;2022-11-15

5. Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality;IUBMB Life;2022-10-18